COVID-19 Diagnostic Testing: Now Available

Please note that IMD Path is not a Collection Center. 
We perform the SARS-CoV-2 (COVID-19) RT-PCR Assay and are available to work with corporate clients and other high volume collection opportunities.
We do not test on an individual patient basis.

Utilization of the IMD Path-SARS-CoV-2 (Covid-19) RT-PCR Assay

Among the main features of this testing IMD:

  • Strives to meet it’s goal of a 1-2 Business Day Turnaround Time for all patient and client specimens upon receiving

  • Provide Physician Guided Support through each testing checkpoint

  • Provide all clients and offices with test logistics, collection kits, and oversee Health Department Certified Notification of Results

Testing Media Options

Nasal Swab

Nasopharyngeal Swab

Oropharyngeal Swab

Statement of Compliance

This test is a modification of the FDA EUA-authorized assay, CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. The modification is validated using a bridging study and is permitted under the FDA modifications policy in the Policy for Coronavirus Disease-2019 Tests. The bridging study was performed by lntegrated Molecular Diagnostics Pathology, Inc. (IMD Path), 12635 E. Montview Blvd., Suite 360, Aurora, CO 80045. This test has not been cleared or approved by the FDA, however, such clearance/approval is not required, as the laboratory is regulated and qualified under the Clinical laboratory Improvements Amendments (CLIA) to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research use.